Iron metabolism and drug resistance in cancer

Kazan, Hasan Hüseyin; Urfali-Mamatoglu, Cagri; Gündüz, Ufuk

doi:10.1007/s10534-017-0037-7

Cited by 69 publications

(53 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In acute myeloid leukemia (AML), inducing ferroptosis by the ferroptosis activator erastin could significantly increase chemotherapy sensitivity of AML cells to cytarabine and doxorubicin. 20 Consistent with this, the results of our proteomic profiling revealed exosomal proteins related to chemoresistance in DLBCL.…”

Section: Discussionsupporting

confidence: 88%

The Role and Underlying Mechanism of Exosomal CA1 in Chemotherapy Resistance in Diffuse Large B Cell Lymphoma

Feng¹,

Zhong²,

Tang³

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Chemotherapy resistance plays a major role in treatment failure of diffuse large B cell lymphoma (DLBCL). Exosomes are closely related to tumor drug resistance. Herein, the expression of exosomal proteins in DLBCL and their roles in chemotherapy resistance of DLBCL are explored. Tandem mass tag labeling proteomics was used to perform proteomic profiling in exosomes from DLBCL patients’ serum. The expression of carbonic anhydrase 1 (CA1) in parental, chemo-resistant DLBCL cells and DLBCL patient exosomes was detected. Proliferation of DLBCL following CA1 knockdown was investigated both in vitro and in vivo , along with the effects on nuclear factor κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3) pathways. We identified 54 differentially expressed proteins. We validated that the expression level of exosomal CA1 was higher in chemo-resistant DLBCL cells than in chemo-sensitive counterparts. Knockdown of CA1 inhibited the growth of DLBCL via inhibiting the activation of NF-κB and STAT3 signaling pathways both in vitro and in vivo . An increased expression level of exosomal CA1 was associated with poorer prognosis, and exosomal CA1 could be used as a biomarker to predict chemotherapeutic efficacy. Our study suggests that exosomal CA1 can promote chemotherapy resistance in DLBCL via the NF-κB and STAT3 pathways, and it can serve as a biomarker for DLBCL prognosis.

show abstract

Section: Discussionsupporting

confidence: 88%

The Role and Underlying Mechanism of Exosomal CA1 in Chemotherapy Resistance in Diffuse Large B Cell Lymphoma

Feng¹,

Zhong²,

Tang³

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…Cytoplasmic iron is stored in ferritin, which is an iron storage protein complex that consists of ferritin light chain (FTL) and ferritin heavy chain 1 (FTH1). Finally, the excess iron is exported by the membrane protein ferroportin (an iron efflux pump, also termed as SLC11A3) (39).…”

Section: Ferroptosis and Glioma Temozolomide Resistance The Role Of Imentioning

confidence: 99%

A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis

Qian

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Temozolomide (TMZ) is the first-line chemotherapy drug that has been used to treat glioma for over a decade, but the benefits are limited by half of the treated patients who acquired resistance. Studies have shown that glioma TMZ resistance is a complex process with multiple factors, which has not been fully elucidated. Ferroptosis, which is a new type of cell death discovered in recent years, has been reported to play an important role in tumor drug resistance. The present study reviews the relationship between ferroptosis and glioma TMZ resistance, and highlights the role of ferroptosis in glioma TMZ resistance. Finally, the investigators discussed the future orientation for ferroptosis in glioma TMZ resistance, in order to promote the clinical use of ferroptosis induction in glioma treatment.

show abstract

“…Iron metabolism regulates carcinogenesis. [20][21][22] Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and third most common cause of cancer-related death. 23 The liver is the primary iron storage organ and is crucial to iron metabolism.…”

Section: Introductionmentioning

confidence: 99%

Iron metabolism gene expression and prognostic features of hepatocellular carcinoma

Shen

Zhao

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Iron metabolism is crucial to hepatocellular carcinoma progression and is a key determinant of prognosis. Protein-protein interactions within the iron metabolism gene network were analyzed using the European Molecular Biology Laboratory's Search Tool for Recurring Instances of Neighbouring Genes/Proteins database. We obtained 423 liver hepatocellular carcinoma gene expression profiles from the Cancer Genome Atlas database. The expression and pathway enrichment of representative iron intake genes (TFRC and DMT1), utilization genes (FTH1, FTL, HIF1A, HMOX1, SLC25A37, and SLC25A38), and efflux genes (FLVCR1 and SLC40A1) was investigated in tumor and adjacent tissues. We determined the relationship between iron metabolism and the prognostic features of liver hepatocellular carcinoma. The liver metabolism genes TFRC and FLVCR1 were related to survival, disease status, and prognosis in patients with hepatocellular carcinoma. Our results provide novel insight into liver cancer therapy.

show abstract

Iron metabolism and drug resistance in cancer

Cited by 69 publications

References 87 publications

The Role and Underlying Mechanism of Exosomal CA1 in Chemotherapy Resistance in Diffuse Large B Cell Lymphoma

The Role and Underlying Mechanism of Exosomal CA1 in Chemotherapy Resistance in Diffuse Large B Cell Lymphoma

A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis

Iron metabolism gene expression and prognostic features of hepatocellular carcinoma

Contact Info

Product

Resources

About